{"id":"NCT02269475","sponsor":"AstraZeneca","briefTitle":"A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years","officialTitle":"A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2014-10-21","resultsPosted":"2015-12-03","lastUpdate":"2017-04-04"},"enrollment":1369,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Japanese Children Age 7 Years Through 18 Years"],"interventions":[{"type":"DRUG","name":"MEDI3250","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MEDI3250","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study is designed to gather the efficacy, safety and tolerability data in Japanese children 7 to 18 years of age that would support approval of MEDI3250 in Japan.","primaryOutcome":{"measure":"the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)","timeFrame":"through the end of the influenza surveillance period, up to end Apr (6 months)","effectByArm":[{"arm":"MEDI3250","deltaMin":0,"sd":null},{"arm":"Placebo","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":868},"commonTop":["nasopharyngitis","upper respiratory tract inflammation","rhinorrhoea","Diarrhoea","Bronchitis"]}}